Video

When to Initiate Treatment for ITP

For High-Definition, Click

The goal of idiopathic thrombocytopenic purpura (ITP) treatment, explains Ivy Altomare, MD, is to treat active bleeding or reduce the risk of bleeding. Determining when to treat a patient with ITP depends on several factors, says Howard A. Liebman, MD, including patient preference and clinical manifestations.

The majority opinion is that patients should consider treatment, if they are not bleeding, only when platelet counts are less than 30,000. Keith McCrae, MD, states that a sedentary person’s platelet count can go quite low, perhaps even below 20,000, before therapy is required. Individuals with a platelet count around 30,000 do not usually have clinically significant bleeding that would put them at risk.

It is also important to consider patient characteristics, such as age and comorbidities, Altomare notes. Older individuals with coronary artery disease taking antiplatelet therapy may be at higher risk of bleeding.

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study